10-Q: Zynex Reports Steep Losses Amid Tricare Payment Suspension and SEC Investigation, Raising Going Concern Doubts

Zynex, Inc. disclosed significant net losses and a substantial revenue decline for the second quarter and first half of 2025, primarily due to a temporary payment suspension from Tricare and reduced device orders, while also revealing an SEC investigation and expressing substantial doubt about its ability to continue as a going concern.

Summary

• Net loss for the three months ended June 30, 2025, was $20.0 million, a significant decline from net income of $1.2 million in the same period of 2024.
• Net loss for the six months ended June 30, 2025, was $30.4 million, compared to net income of $1.2 million for the same period in 2024.
• Total net revenue decreased by 55.2% to $22.3 million for the three months ended June 30, 2025, from $49.9 million in the prior year period.
• Total net revenue decreased by 49.3% to $48.9 million for the six months ended June 30, 2025, from $96.4 million in the prior year period.
• Device orders decreased by 20% for the three months and 12% for the six months ended June 30, 2025, compared to the same periods in 2024.
• Tricare, historically representing 20-25% of annual revenue, temporarily suspended payments due to allegations of misrepresentation of supplies, equipment, and diagnoses; the suspension continues as of June 2025.
• The company recognized only $0.6 million in revenue from Tricare for the three months and $2.8 million for the six months ended June 30, 2025, equal to cash received, and fully reserved all other Tricare-related receivables.
• Workforce reductions in Q1 2025 (approximately 15%) and June 2025 (additional 14%) are expected to result in annualized cost savings of approximately $35.0 million and $5.0 million, respectively.
• The SEC initiated an investigation with voluntary document requests on June 11, 2025, and June 30, 2025, to determine potential federal securities law violations.
• Substantial doubt exists about the company's ability to continue as a going concern for the next 12 months, contingent on refinancing or amending $60.0 million in convertible senior notes maturing May 15, 2026, or securing necessary financing.
• Cash and cash equivalents decreased to $17.5 million as of June 30, 2025, from $39.6 million as of December 31, 2024.
• Working capital shifted from a surplus of $58.3 million as of December 31, 2024, to a deficit of $28.3 million as of June 30, 2025.

Sentiment

Score: 2

Explanation: The company reported substantial net losses, a near 50% revenue decline, and a shift to a working capital deficit. The ongoing Tricare payment suspension, SEC investigation, and multiple lawsuits create significant operational and financial uncertainty. Management has expressed substantial doubt about the company's ability to continue as a going concern, highlighting severe liquidity issues and the urgent need for refinancing or new capital.

Positives

• The company is cooperating with the SEC investigation and providing responsive documents on a rolling basis.
• Workforce reductions implemented in Q1 2025 and June 2025 are projected to yield significant annualized cost savings of approximately $40.0 million.
• A 510(k) application was submitted to the FDA for the NiCO device, indicating progress in product development.
• Management is committed to maintaining a strong internal control environment and is developing remediation plans for the identified material weakness.

Negatives

• Reported a net loss of $30.4 million for the six months ended June 30, 2025, a significant deterioration from net income in the prior year.
• Experienced a substantial 49% decrease in total net revenue for the six months ended June 30, 2025, compared to the same period in 2024.
• Tricare, a major government payer, has temporarily suspended payments due to allegations of misrepresentation, severely impacting revenue and cash flow.
• Management has concluded that substantial doubt exists about the company's ability to continue as a going concern for the next 12 months.
• Cash and cash equivalents significantly declined to $17.5 million, and working capital shifted to a $28.3 million deficit as of June 30, 2025.
• The company is under investigation by the SEC for potential violations of federal securities laws.
• Facing a securities fraud class action and a shareholder derivative action alleging breaches of fiduciary duties and gross mismanagement.
• Identified a material weakness in Information Technology General Controls (ITGCs) affecting financial reporting.
• Device orders decreased by 12% for the six months ended June 30, 2025, partly due to a 50% reduction in the sales force.

Risks

• The imposition of new duties, tariffs, trade barriers, and retaliatory countermeasures may have a material adverse effect on business, financial condition, and results of operations.
• Increased costs of manufactured products and components sourced outside the U.S. due to tariffs could reduce gross margin.
• The Tricare Payment Suspension, whether temporary or permanent, has resulted and may in the future result in an adverse impact on revenues and profits.
• Inability to raise sufficient capital, reduce expenditures, and/or execute on the business plan may prevent the company from continuing as a going concern.
• No assurance that the company will be able to amend or refinance the $60.0 million convertible senior notes maturing May 15, 2026, or that terms will be acceptable.
• Failure to redeem or refinance the convertible senior notes could have a material adverse impact on operations.
• No assurance that the company will be able to raise additional capital to fund operations with acceptable terms, or at all.
• Potential requirement to significantly delay, scale back, or discontinue product development, pursue company sale at a loss, or file for bankruptcy/cease operations if liquidity does not improve.
• Substantial costs and adverse outcomes in litigation, regulatory investigations, and other legal matters.
• Securities fraud class action and shareholder derivative action could result in further legal matters, government enforcement actions, or additional private litigation.
• The SEC investigation may result in charges, material damages, fines, penalties, enforcement actions, or civil/criminal proceedings.
• Ongoing investigative demands, subpoenas, and document requests from various government organizations could lead to government actions, damages, fines, sanctions, loss of licensure, or exclusion from government programs.
• Litigation and regulatory investigations, regardless of merits, are costly, divert management attention, and may adversely affect reputation and product demand.
• Fluctuations in tax obligations and effective tax rate and realization of deferred tax assets may result in volatility of operating results and adversely affect financial condition.
• Future effective tax rates could be subject to volatility or adversely affected by changes in valuation of deferred tax assets/liabilities, timing/amount of tax valuation allowance release, changes in tax laws/regulations, or lower/higher than anticipated earnings in different jurisdictions.
• Audits of income, sales, and other transaction taxes by U.S. federal, state, and local taxing authorities could have an adverse effect on operating results and financial condition.

Future Outlook

Management has concluded that substantial doubt exists about the company's ability to continue as a going concern for 12 months from the financial statement issuance date. This is dependent on its ability to obtain consent from creditors or terminating, amending, or refinancing the agreements governing the $60.0 million outstanding convertible senior notes which mature on May 15, 2026, or to obtain the necessary financing to meet its obligations. There is no assurance that the company will be able to amend or refinance the convertible senior notes, or that the terms will be acceptable or advantageous. Failure to improve liquidity could lead to significant delays, scaling back, or discontinuation of product development, sale of the company at a loss, or bankruptcy/cessation of operations. The company is currently evaluating the impact of the 'One Big Beautiful Bill Act' (OBBBA) but does not expect it to have a material effect on its consolidated financial statements for the quarter ended September 30, 2025.

Management Comments

• "We held a meeting with Tricare in April 2025 and believe we had good evidence to get payments reinstated."
• "As directed by Tricare, we continue to support both existing patients and new patients as prescriptions are received."
• "We are cooperating with the SEC in its investigation, and are, on a rolling basis, providing all responsive documents to both requests."
• "Our management is committed to maintaining a strong internal control environment."
• "Our management, including our Chief Executive Officer and Chief Financial Officer, do not expect that our disclosure controls and procedures or our internal control over financial reporting will prevent all errors and all fraud."

Industry Context

The company operates in the medical devices segment, specializing in electrotherapy and pain management products, which are subject to stringent FDA regulation and require physician prescriptions. The significant challenges with Tricare, a major government payer, underscore the inherent risks associated with third-party reimbursement policies and regulatory scrutiny in the healthcare industry. The company's focus on non-invasive pain management aligns with broader industry trends seeking alternatives to traditional medication, but its current financial and legal issues highlight the operational complexities and compliance demands within this sector.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results to benchmark against industry standards, thus a detailed assessment in this context cannot be made based solely on the provided document.

Management Changes

Corporate Governance

Legal Proceedings

• Putative Class Action Complaint: Filed on March 20, 2025, alleging securities fraud (violations of Section 10(b) of the Securities Exchange Act of 1934 and Rule 10b-5) against the company, CEO Thomas Sandgaard, and CFO Daniel Moorhead, for failing to disclose material adverse facts, including an oversupply scheme, inflated revenue, and concealed scrutiny from insurers. Seeks class certification and unspecified damages.
• Shareholder Derivative Complaint: Filed on July 9, 2025, against officers and directors, alleging breaches of fiduciary duties, waste of corporate assets, unjust enrichment, gross mismanagement, and/or aiding and abetting, as well as violations of Section 14(a) of the Securities Exchange Act of 1934. Seeks restitution and disgorgement of profits.
• SEC Investigation: Received voluntary (non-subpoena) requests for documents on June 11, 2025, and June 30, 2025, from the SEC in connection with an investigation to determine whether violations of federal securities laws have occurred. The company is cooperating.
• Other Government Investigations: Currently responding to investigative demands, subpoenas, and formal document/records requests from various government organizations including the Department of Justice, Department of Health and Human Services-Office of Inspector General, California Department of Insurance, and Colorado Attorney General, related to operations, compliance, finance, data privacy, and other business matters.

Related Party Transactions

• On March 13, 2025, the disinterested Board and Audit Committee approved the purchase of 1,700,000 common shares of ZYXI from Thomas Sandgaard, Chairman, President, Chief Executive Officer, and Principal Executive Officer, at the closing market price of $2.905 per share, totaling $4,938,500. The Board deemed this in the company's best interest, believing the stock was undervalued and it was a good use of funds.

Stakeholder Impact

• Shareholders: Significant net losses, revenue decline, going concern doubt, and ongoing legal/regulatory issues pose substantial risk to investment value. The stock repurchase from the CEO might be viewed negatively by some given the company's liquidity issues.
• Employees: Workforce reductions (15% in Q1 2025, additional 14% in June 2025) indicate job insecurity and potential morale issues.
• Customers (Tricare patients): Continued support for existing and new patients despite payment suspension, but the underlying allegations could impact service perception or availability in the long term.
• Creditors (Convertible Senior Notes holders): The $60.0 million notes maturing in May 2026 face uncertainty regarding refinancing or amendment, raising concerns about repayment.
• Suppliers: Concentration risk with a few significant vendors (67% from four vendors in Q2 2025) could be impacted by the company's financial distress.

Next Steps

• Continue supporting existing and new Tricare patients as prescriptions are received, despite the ongoing payment suspension.
• Cooperate with the SEC investigation by providing responsive documents on a rolling basis.
• Pay the majority of workforce reduction costs in the second and third quarters of 2025.
• Identify and appoint a new Chief Financial Officer following Daniel J. Moorhead's resignation.
• Daniel J. Moorhead is expected to enter into a consulting agreement to assist with the CFO transition.
• Evaluate the impact of the 'One Big Beautiful Bill Act' (OBBBA) on financial statements for the quarter ended September 30, 2025.
• Develop and implement remediation plans to address the identified material weakness in internal control over financial reporting.
• Vigorously defend against the securities fraud class action and shareholder derivative action.
• Address the $60.0 million convertible senior notes maturing May 15, 2026, through consent from creditors, termination, amendment, or refinancing.
• Potentially raise additional capital to fund operations.

Key Dates

Recommendation

The company faces severe financial distress, evidenced by substantial net losses, a near 50% revenue decline, and a shift to a working capital deficit. Management has explicitly stated "substantial doubt" about the company's ability to continue as a going concern, highlighting critical liquidity issues and the urgent need to refinance $60 million in convertible notes or raise new capital, with no assurance of success. Furthermore, the ongoing Tricare payment suspension, an active SEC investigation into potential federal securities law violations, and multiple class action and derivative lawsuits create immense regulatory, legal, and reputational risks. These factors collectively point to a highly precarious financial position and significant downside risk for investors.

Keywords

Medical Devices, Electrotherapy, Pain Management, SEC Investigation, Tricare, Convertible Senior Notes, Going Concern, Workforce Reduction, Financial Performance, Quarterly Report, Zynex, ZYXI, Healthcare, Regulatory Compliance, Litigation, Corporate Governance